Authorised Phase I and Phase II (Integrated)- Other post-COVID syndrome (long COVID)

Locating microclots with PET in post-COVID syndrome

EU CTIS ID: 2025-522348-42-00

What this study is testing

To assess whether we are able to visualize and quantify a difference in amyloid containing microclots between post-COVID patients and controls using total-body dynamic [18F]flutemetamol PET.

  • Phase I and Phase II (Integrated)- Other

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • The subject was diagnosed with symptomatic COVID-19, confirmed by a positive PCR for SARS-CoV-2.
  • The subject is at least 12 months after being diagnosed with COVID-19.
  • The subject is in the range 40-65 years of age (to ensure radiation safety).
  • The subject has sufficient command of the Dutch language.
  • The subject is able to undergo the (PET) scanning procedures.

You likely can't join if

  • The subject has other medical conditions linked to amyloid-formation, such as diabetes, rheumatoid arthritis or neurodegenerative disorders.
  • The subject is unable to undergo scanning procedures due to for example claustrophobia, severe back pain or trypanophobia (fear of needles).
  • The subject is using anti-coagulant drugs.
  • The subject is a female of childbearing potential who is not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

ObesityType 2 diabetesType 1 diabetesPrediabetesWeight lossMetabolic syndromeHigh cholesterolHigh triglyceridesHigh blood pressurePCOSHypothyroidismThyroid diseaseGoutFatty liver disease (NAFLD/NASH)Heart failureCoronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.